Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease

Journal of Rheumatology

Volumn 30, Issue 7, 2003, Pages 1624-1625

  Michel, Marc ^a,b   Duvoux, Cristophe ^c   Hezode, Cristophe ^c   Cherqui, Daniel ^c  

^a Serv Med Nucl   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c NONE

Author keywords

Adult onset still's disease; Fulminant hepatitis; Infliximab

Indexed keywords

COTRIMOXAZOLE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; PREDNISONE; STEROID; TACROLIMUS;

ADULT ONSET STILL DISEASE; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER TRANSPLANTATION; MYALGIA; PNEUMOCYSTIS PNEUMONIA; POLYARTHRITIS; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HEPATITIS B; HUMANS; LIVER; LIVER FAILURE; STILL'S DISEASE, ADULT-ONSET;

EID: 0038504830     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 1999;354:1932-9.
2. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
4. Bondenson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab; REMICADE. Int J Clin Pract 2001;55:211-6.
5. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001;76:84-6.
6. Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double stranded DNA antibodies following infliximab therapy [letter]. Arthritis Rheum 2002;44:1966-7.
7. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30.
8. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine 1991;10:118-35.
9. Janssen HLA, Van Laar JM, Van Hoek B, Den Ottolander GJ, Van Krieken JHJM, Breedveld FC. Severe hepatitis and pure red cell aplasia in Adult Still's disease. Dig Dis Sci 1999;44:1639-42.
10. McFarlane M, Harth M, Wall WJ. Liver transplant in adult Still's disease. J Rheumatol 1997;24:2038-41.
11. Kraetsch HG, Antoni C, Kelden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab; first experiences. Ann Rheum Dis 2201;60 Suppl 3:55-7.
12. Hussain MJ, Lau JY, Williams R, Vergani D. Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection. J Clin Pathol 1994;47:1112-5.
13. Peterson CJ, Wener MH, Hsu FC, Simkin PA. Safety of TNF-a antagonists in patients with rheumatoid arthritis and chronic hepatitis C [abstract]. Arthritis Rheum 2001;44 Suppl 9:156.
14. Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191-2.